Reuters logo
Celgene abandons Crohn's disease drug trials
October 19, 2017 / 8:44 PM / in a month

Celgene abandons Crohn's disease drug trials

Oct 19 (Reuters) - Celgene Corp said on Thursday it would stop two studies of its drug for an inflammatory bowel disease and would not begin a third, following a recommendation by a data monitoring committee.

The drug, mongersen, was being tested in late-stage and extension studies as a treatment for Crohn’s disease.

The company’s shares were halted in after-market trading. (Reporting by Tamara Mathias in Bengaluru)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below